204 related articles for article (PubMed ID: 26723936)
1. [New therapies in thyroid cancer].
López Mondéjar P; Galofré JC
Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
[No Abstract] [Full Text] [Related]
2. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
3. Update on Targeted Therapy in Medullary Thyroid Cancer.
Okafor C; Hogan J; Raygada M; Thomas BJ; Akshintala S; Glod JW; Del Rivero J
Front Endocrinol (Lausanne); 2021; 12():708949. PubMed ID: 34489865
[TBL] [Abstract][Full Text] [Related]
4. Foreword.
Wells S
Recent Results Cancer Res; 2015; 204():v-vi. PubMed ID: 26714327
[No Abstract] [Full Text] [Related]
5. Multikinase inhibitors in thyroid cancer.
Licitra L; Locati LD
Ann Oncol; 2012 Sep; 23 Suppl 10():x328-33. PubMed ID: 22987985
[No Abstract] [Full Text] [Related]
6. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
7. Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.
Brose MS
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):7-12. PubMed ID: 27168342
[No Abstract] [Full Text] [Related]
8. EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.
Sherman SI
Trans Am Clin Climatol Assoc; 2019; 130():255-265. PubMed ID: 31516190
[TBL] [Abstract][Full Text] [Related]
9. Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.
Rajabi S; Hedayati M
Mol Diagn Ther; 2017 Dec; 21(6):607-620. PubMed ID: 28698976
[TBL] [Abstract][Full Text] [Related]
10. [Refractory thyroid cancers].
Schlumberger M; Chougnet C; Baudin E; Leboulleux S;
Presse Med; 2011 Dec; 40(12 Pt 1):1189-98. PubMed ID: 22078085
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted therapies for patients with refractory thyroid cancer.
Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
[TBL] [Abstract][Full Text] [Related]
12. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V; Carlomagno F; Li HY; Santoro M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Hadoux J; Schlumberger M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
[TBL] [Abstract][Full Text] [Related]
14. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
15. [Use of new molecules in the treatment of advanced thyroid cancer].
Galofré JC; Gómez-Sáez JM; Álvarez Escola C; Álvarez García E; Anda Apiñaniz E; Calleja A; Donnay S; Lucas-Martin A; Menéndez Torre E; Navarro González E; Pereg V; Pérez Corral B; Santamaría Sandi J; Riesco Eizaguirre G; Zafón Llopis C;
Endocrinol Nutr; 2011 Oct; 58(8):381-6. PubMed ID: 21924966
[No Abstract] [Full Text] [Related]
16. Mouse models of medullary thyroid cancer and developing new targeted therapies.
Paragliola RM; Torino F; Papi G; Locantore P; Pontecorvi A; Corsello SM
Expert Opin Drug Discov; 2016 Oct; 11(10):917-9. PubMed ID: 27541085
[No Abstract] [Full Text] [Related]
17. Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.
Tuttle RM; Brose MS
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):12-3. PubMed ID: 27168343
[No Abstract] [Full Text] [Related]
18. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
Bruce JY; Bible KC; Chintakuntlawar AV
Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
[No Abstract] [Full Text] [Related]
19. Nucleophosmin delocalization in thyroid tumour cells.
Pianta A; Puppin C; Passon N; Franzoni A; Romanello M; Tell G; Di Loreto C; Bulotta S; Russo D; Damante G
Endocr Pathol; 2011 Mar; 22(1):18-23. PubMed ID: 21258971
[TBL] [Abstract][Full Text] [Related]
20. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
